Greater brand-drug adoption fuels Asia-Pacific breast cancer market

Due to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics market value will climb from a value of $1.5 billion in 2013 to $2.5 billion by 2020, expanding at a compound annual growth rate (CAGR) of 7.6%.

According to a new report from business intelligence provider GBI Research, Japan had the largest market in 2013 with a share of 58%, followed by China and Australia, with respective shares of 21% and 16%. Despite India having the lowest share in 2013, the country will witness the fastest growth over the forecast period, with a CAGR of 13.8%.

Saurabh Sharma, analyst for GBI Research, says: “The use of targeted therapies is expected to increase in the APAC markets as patient access to these more expensive agents improves, aided by the entry of a biosimilar version of trastuzumab.”